DEKA
31.1.2024 16:01:35 CET | Business Wire | Press release
DEKA, an Italian subsidiary of the El.En. Group, listed on the Eurostar Next of Borsa Italiana (ELN.MI), specialized in the development and production of pioneering Energy Based devices for aesthetics and surgery, on the occasion of the 25th IMCAS World Congress, which will be held in Paris from February 1-3, has announced the launch of 4 new laser platforms which integrate the “PRO” line, presented during the World Congress of Dermatology (WCD) held in Singapore last July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131482600/en/
(Photo: DEKA)
After the success obtained in the US and Canada, DEKA, with its laser systems, among which the very famous lunch-time CoolPeel® treatment for face rejuvenation, and epilation is now introducing the TETRA PROTM, MOTUS PROTM, SMARTXIDE PROTM and TOROTM platforms to the market.
With these new solutions DEKA transforms traditional dermatology laser technology paradigms, aesthetic medicine and dermatologic surgery, opening them to new practical frontiers.
Riccardo Stocchi – The company’s Innovation Manager stated: “The enthusiasm for the success we obtained with the PRO line and the ability to anticipate physicians’ requests, have turned, once again, into DEKA’s ability to create innovation, paying close attention to product positioning and correct segmentation of the reference market, responding with breakthrough technologies, which provide enormous benefits to both operators and patients. The road marked by DEKA, which has invested substantially in research and development and clinical research, obtaining extraordinary results, highlights, besides high efficacy and safety standards, maniacal attention to detail, from equipment design to software usability, with more and more innovative graphic user interfaces, which are absolutely intuitive and user friendly".
Paolo Salvadeo, DEKA’s CEO and El.En.’s General Manager, echoes Mr. Stocchi by adding: "These four new laser solutions, which see the light after few months from the launch of the PRO line, are the umpteenth demonstration of the efficacy of our organizational and R&D model. The path is marked. Thanks to DEKA’s strong aid, our group, in the medical segment, not only wishes to assert itself as the first player in the medical laser segment worldwide, but also to prospectively maintain a strong leadership position with regard to the market and competition. It is a fast-running machine, which we have no intention of slowing down".
Talking specifically about the four DEKA novelties, TETRA PROTM carries on the success seen by the birth of the “CoolPeel®” treatment/phenomenon in the US. TETRA PROTM, with its 40W of power, is the evolution of the 30W “SmartXide Tetra” CO2 laser, with a broader scanning area and treatment time reduction by 25%. The new “TETRA MOVEO” scanning mode also allows for treatment time reduction of the Made in the USA “CoolPeel®”. The ability to execute different treatments, from traditional and fractional rejuvenation, to various types of scar tissue, also deep, ultrafast vaporisations and other treatments which fall within various disciplines, completes the versatility of this new technology.
MOTUS PROTM is the latest evolution of the Motus line, Alexandrite laser and Nd:YAG, which has revolutionized the paradigms of epilation thanks to its high efficacy and very high comfort for the patient, also opening itself up to vascular treatments, up to the latest Made in the USA “MOVEO GLO”, which offers a complete face treatment, in the same session, to achieve optimal results at pigmentary, vascular and chrono-photo aging level. The “3 in 1” treatment with “GLO(W)” effect.
New design, more peak power, handled by a new software and mitigated by a new cooling system to carry forward the worldwide success in epilation signed by DEKA, are only a few of the novelties of the MOTUS PROTM technology.
Going back to CO2 Laser technology, SmartXide PROTM replicates the success of its predecessor, SmartXide DOT, the first fractional laser on the market, which has obtained success the world over, in particular in the United States, also known for periocular and blepharoplasty treatments.
Another important novelty is TOROTM, the laser device that the market had long been waiting for to act on more fronts: Spots, tattoos, rejuvenation, ranging from scar tissue to toning, all the way to the DEKAPeel treatment, to quickly intervene on dilated pores and obtain general improvement of cutaneous texture.
2 wavelengths, 1064 and 532 nm Q-Switched, and a third, 785nm, operating in the picosecond range, guarantee treatment efficacy and safety. TOROTM has been engineered especially for those skin types, among which Asian ones, which may benefit from this ultrafast coherent radiation, in terms of treatment efficacy and safety. By means of a pre-set database, which offers several clinical cases and a guided path throughout the various parameters which involve several targets (spot depth, tattoo color, typology of benign pigmented lesions, rejuvenation type and toning), TOROTM guides the physician, whilst guaranteeing treatment efficacy and safety.
Information on DEKA M.E.L.A.
DEKA M.E.L.A. is a subsidiary of the EL.EN. multinational Group which has been the leader in the laser work for 40 years.
This Italian company, headquartered in Florence, has its roots in a culture whose dominant characteristic is excellence of thought. Thanks to its priceless cultural heritage and its unique historical background, DEKA enshrines a promise of universal value in its vision: Transforming each scientific discovery into a solid benefit for physicians and patients, and translate each technological innovation into ongoing improvement in its product and services range to ameliorate the quality of people’s lives.
DEKA means reaching perfection and excellence and it is “10”, the perfect number according to the philosopher and mathematician Pythagoras.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131482600/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Digital Trust Index 2026: AI Skepticism and Identity Access Friction Are Costing Revenue31.3.2026 14:00:00 CEST | Press release
93% of IT leaders are deploying GenAI, but only 23% of consumers trust companies that use AI to handle their data. Friction at sign-up, login, and onboarding is causing customer abandonment and revenue loss, with 68% of consumers switching due to website issues. 69% of consumers trust companies more when MFA (multi factor authentication) is used, 68% say the same about passkeys. Thales today released the 2026 Digital Trust Index, one of the most comprehensive global studies of digital trust. Surveying more than 15,000 consumers, business partners, and IT decision makers across 13 industries, the research reveals that digital trust is won or lost during sign-up, login, and throughout the lifecycle of personal data handling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331668723/en/ Beyond banking’s clear lead, the rest of the sectors fall well behind in consumer confidence. ©Thales Consumer Trust is Won or Lost at Login
Tanner Pharma Group and Biodexa Launch Global Early Access Program for FAP Patients31.3.2026 14:00:00 CEST | Press release
Tanner Pharma Group, a global provider of specialty medicine access solutions, and Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing innovative products for gastrointestinal cancers, have announced a strategic partnership to enable global access to eRapa for patients with Familial Adenomatous Polyposis (FAP) through an Early Access / Named Patient Program. FAP is characterized by a proliferation of polyps in the colon and/or rectum, usually occurring in mid-teens. There is no approved therapeutic option, and surgical resection remains the standard of care. eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus), an mTOR inhibitor involved in cellular metabolism, growth, and proliferation and activated during tumorigenesis. mTOR has been shown to be over-expressed in FAP polyps, supporting the rationale for its use in treatment. Through this collaboration, Tanner Pharma will facilitate compliant, controlled access to eRapa
SLB and Azule Energy Scale Enterprise Digital Operations to Strengthen Energy Delivery in Angola31.3.2026 14:00:00 CEST | Press release
SLB’s enterprise digital platform will enhance execution reliability across Azule’s operations in Angola Global technology company SLB (NYSE: SLB) today announced a three-year agreement with Azule Energy to continue and expand the use of its enterprise digital platform across Azule’s operations in Angola. The platform will help Azule drive more consistent execution, accelerate decision-making, and support reliable energy delivery across its portfolio. Azule Energy — a joint venture of bp and Eni and the largest independent energy producer in Angola — operates some of the region’s most complex assets. The agreement builds on two years of Delfi™ use within Azule’s reservoir organization, where the platform supports reservoir studies, modelling, simulation, and well planning workflows, and supports enterprise-scale digital integration by connecting reservoir workflows with broader operational data environments over time. “Azule operates large, complex energy assets where execution reliabi
Esri and RoboGarden Sign Strategic MOU to Advance Geospatial and Geomatics Education31.3.2026 14:00:00 CEST | Press release
Agreement Explores New Models for Digital Learning, Academic Collaboration, and Global Workforce Readiness Esri and RoboGarden have signed an MOU to explore strategic collaboration that broadens access to modern GIS and geomatics education. RoboGarden, a Canadian EdTech company, offers gamified and scalable digital learning solutions for academic institutions, governments, and industry. The MOU outlines joint exploration of academic pathways, improved regional coordination, and potential creation of a Geospatial & Geomatics Virtual Academy. The agreement focuses on enhancing digital learning delivery, expanding localized e-learning opportunities, and supporting global workforce development in high-demand technology fields. To stay informed about Esri’s education initiatives and resources, visit esri.com/en-us/industries/education/overview. Esri, the global leader in geographic information system (GIS) technology, today announced the signing of a Memorandum of Understanding (MOU) with R
ExaGrid Named a Finalist for the Network Computing Awards 202631.3.2026 14:00:00 CEST | Press release
ExaGrid nominated in 11 Categories for annual industry awards ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in 11 categories for the annual Network Computing Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331887370/en/ ExaGrid has become a finalist in the following categories: Data Protection Product of the Year The Return On Investment Award Air Gapped Ransomware Recovery Product of the Year Storage Product of the Year Hardware Product of the Year The Customer Service Award Enterprise Product of the Year New Product of the Year Product of the Year Company of the Year Additionally, ExaGrid is nominated for the “Bench Tested Product of the Year” award determined by judges after an independent product review of the ExaGrid Tiered
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
